mucositis


Also found in: Wikipedia.

mucositis

 [mu″ko-si´tis]
inflammation of a mucous membrane.

mucositis

(myū-kō-sī'tis),
Inflammation of a mucous membrane.
[mucosa + -itis]

mucositis

[myo̅o̅′kōsī′tis]
any inflammation of a mucous membrane, such as the lining of the mouth and throat.

mucositis

Inflammation of a mucosa which, in the GI tract, appears as oral ulcers. See Stomatitis.

mu·co·si·tis

(myūkō-sītis)
Inflammation of a mucous membrane
[mucosa + -itis]

mucositis (mū´kōsī´tis),

n an inflammation of the mucous membrane.
mucositis, chronic atrophic senile,
n oral mucosal inflammation characterized by atrophy and found primarily in elderly women.
mucositis, fusospirochetal,
n oral mucosal inflammation associated with fusiform and spirochetal microorganisms.

mucositis

inflammation of a mucous membrane.
References in periodicals archive ?
The Phase 2 proof-of-concept clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer patients remains consistent with prior guidance.
However, while in vivo animal models of chemotherapy and radiotherapy-induced oral mucositis have been successfully established, alternative methods such as in vitro tools for mucositis are still missing.
Oral mucositis is a common side effect of cancer treatments with approximately 1.
An evidence-based protocol for dental care with specific treatment modalities, including the prevention and treatment of oral mucositis (OM), is included.
Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study.
The most important side effects of oncologic therapy are ulcerations, alopecia, thrombocytopenia, neutropenia and oropharyngeal mucositis (OM).
Oral mucositis (OM) is a common side effect of chemotherapy and radiation therapy.
Susan Sencer, MD, medical director, Hematology/Oncology, presented findings on the use of the homeopathic agent Traumeel S in children with mucositis undergoing stem cell transplantation (SCI).
The GI Company's lead Phase II clinical candidate, Intestinal Trefoil Factor (ITF), is an endogenous protein in Phase II development for the treatment oral mucositis, a common, debilitating complication resulting from high-dose chemotherapy and / or radiotherapy.
Purpose: Oral mucositis is a common and severe complication of head and neck radiation therapy.
SAN ANTONIO -- Saforis has been shown to reduce the incidence and severity of oral mucositis in patients undergoing chemotherapy, Douglas E.
Thousand Oaks, CA, announced the US Food and Drug Administration (FDA) has approved Kepivance (palifermin), the first and only therapy to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.